In a recent review, no statistically significant increase in risk of LEA was observed for people with type 2 diabetes and peripheral arterial disease prescribed SGLT2 inhibitors compared to GLP‐1RAs. This evidence concerns the gene SLC5A2 and peripheral arterial disease.